|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
|
29907952 |
2018 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In EGFR mutant lung cancer, modeling of acquired resistance (AR) with drug-sensitive cell lines has identified clinically relevant EGFR tyrosine kinase inhibitor (TKI) resistance mechanisms such as the second-site mutation, EGFR T790M, amplification of the gene encoding an alternative kinase, MET, and epithelial-mesenchymal transition (EMT).
|
23733853 |
2013 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
|
25074459 |
2014 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
|
27959700 |
2017 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although afatinib inhibited the growth of lung cancer cells with low T790M allele frequencies in preclinical studies, this could not be translated into clinical efficacy in terms of lowering the rate or delaying the time of T790M acquisition.
|
31030101 |
2019 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
|
27433829 |
2016 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
|
29482151 |
2018 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
|
30073261 |
2018 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This review summarizes information about and current treatment strategies for patients with EGFR-mutant lung cancer whose disease progresses on their initial EGFR inhibitor, including those with T790M and other types of acquired resistance.
|
27196961 |
2016 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials have documented their efficacy in patients with <i>EGFR</i>-mutant lung cancer.
|
28416483 |
2017 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
|
23185274 |
2012 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
|
26400668 |
2015 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.
|
30151614 |
2018 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Nowadays, 3rd generation EGFR TKI is widely used for T790M positive 1st and 2nd EGFR-TKI resistant lung cancer patients.
|
28684311 |
2017 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring EGFR(T790M), prior preclinical studies demonstrate that acquired resistance can occur through genomic alterations that activate ERK1/2 signaling.
|
26036643 |
2015 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.
|
17671147 |
2007 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of low-level EGFR T790M mutation in lung cancer tissues.
|
21635547 |
2011 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
As this clinical entity is underrepresented in clinical trials, the practicability of plasma EGFR testing and the optimal dose-response relationship of osimertinib in T790M-positive lung cancer complicated with LM deserves further exploration.
|
28296233 |
2017 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.
|
27811988 |
2016 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had received previous treatment with EGFR tyrosine kinase inhibitors (TKIs), with 2 having concurrent EGFR T790M and 1 additional EGFR C797S.
|
31761448 |
2019 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings suggest that radiotherapy combined HS-10182 is a novel treatment for lung cancer cells which have acquired the T790M mutation.
|
29545967 |
2018 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The clinical features of EGFR T790M-mutant lung cancer were similar to those of sensitive EGFR-mutant lung cancer, except for the overrepresentation of never-smokers and brain metastasis.
|
25450875 |
2015 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Purpose:</b> Acquired <i>EGFR</i> T790M mutations are the most frequently identified resistance mechanism to EGFR tyrosine kinase inhibitors (TKI) in patients with <i>EGFR</i>-mutant lung cancers.
|
28954786 |
2017 |
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cumulative survival from the time of rebiopsy to the last follow-up was significantly longer in patients with T790M mutation-positive lung cancers (P = .014).
|
30015588 |
2018 |